

Ildar Nurmeev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2884972/publications.pdf>

Version: 2024-02-01

18
papers

448
citations

1478458

6
h-index

1199563

12
g-index

18
all docs

18
docs citations

18
times ranked

318
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	4.6	173
2	Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. <i>Lancet Haematology</i> , 2021, 8, e22-e33.	4.6	82
3	Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. <i>Blood</i> , 2020, 135, 491-504.	1.4	68
4	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52
5	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020, 4, 4632-4639.	5.2	35
6	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2168-2175.	3.4	26
7	Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism. <i>Blood</i> , 2016, 128, 1441-1441.	1.4	4
8	Aneurysm of Upper Limb Arteries in Children: Report of Five Cases. <i>Case Reports in Medicine</i> , 2020, 2020, 1-4.	0.7	3
9	Treatment of the newborn with a floating thrombus in the right atrium: case report. <i>Russian Open Medical Journal</i> , 2019, 8, e0111.	0.3	1
10	Children with lymphatic malformations and their treatment using video-endoscopic equipment. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2020, 65, 232-238.	0.3	1
11	Remote diagnostics and treatment tactics for complex congenital heart defects in newborns. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2020, 65, 239-244.	0.3	1
12	Varicose veins in adolescents: a prospective cohort study. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2021, 66, 183-187.	0.3	1
13	A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	1.5	1
14	THE PROBLEM OF PERMANENT VASCULAR ACCESS IN PATIENTS WITH CONGENITAL COMBINED COAGULATION DISORDER AND THROMBOHEMORRHAGIC SYNDROME (A CLINICAL CASE). <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2012, 11, 193.	0.4	0
15	Momentary radical removal of lymphangioma in children. The results of prospective cohort study in parallel groups. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2019, 64, 189-193.	0.3	0
16	POTENTIALS FOR VIDEO-ENDOSCOPIC REMOVAL OF LYMPHANGIOMAS OF THE SOFT TISSUES IN NEWBORNS. <i>Russian Journal of Pediatric Surgery</i> , 2020, 24, 244-248.	0.2	0
17	The use of recombinant activated factor VII in the treatment of postoperative bleedings in children with congenital heart defects. <i>Vrach</i> , 2021, 32, 50-55.	0.1	0
18	Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial. <i>Blood</i> , 2020, 136, 24-25.	1.4	0